title: Nanotechnology-mediated targeting of tumor angiogenesis.
abstract: Angiogenesis is disregulated in many diseased states, most notably in cancer. An emerging strategy for the development of therapies targeting tumor-associated angiogenesis is to harness the potential of nanotechnology to improve the pharmacology of chemotherapeutics, including anti-angiogenic agents. Nanoparticles confer several advantages over that of free drugs, including their capability to carry high payloads of therapeutic agents, confer increased half-life and reduced toxicity to the drugs, and provide means for selective targeting of the tumor tissue and vasculature. The plethora of nanovectors available, in addition to the various methods available to combine them with anti-angiogenic drugs, allows researchers to fine-tune the pharmacological profile of the drugs ad infinitum. Use of nanovectors has also opened up novel avenues for non-invasive imaging of tumor angiogenesis. Herein, we review the types of nanovector and therapeutic/diagnostic agent combinations used in targeting tumor angiogenesis.
authors.affiliation: BWH-HST Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Science and Technology, Cambridge, MA 02139, USA. shiladit@mit.edu.
authors.forename: Deboshri
authors.initials: D
authors.lastname: Banerjee
authors.forename: Rania
authors.initials: R
authors.lastname: Harfouche
authors.forename: Shiladitya
authors.initials: S
authors.lastname: Sengupta